<clinical_study>
<study_id>
<org_name>
  BioProducts
</org_name>
<org_full_name>
  Bio Products Laboratory
</org_full_name>
<org_study_id>
  GMX02
</org_study_id>
<nct_id>
  NCT00504075
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  A Study to Find How Safe and Effective GAMMAPLEX&#174; is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
</textblock>
</brief_title>
<official_title>
<textblock>
  A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX&#174; in Chronic Idiopathic Thrombocytopenic Purpura
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Bio Products Laboratory
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
  Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
 To determine  if   GAMMAPLEX  raises  the  platelet  count  of  subjects  with  chronic  ITP  to  a  threshold  of  50  x  109/L,  similar  to  that  of  a  historical        response &gt;60%. Also to  assess the  safety  of  GAMMAPLEX           and determine  if    platelet  counts    are maintained at 50  x  109/L  in  subjects  with  chronic  ITP              for. 
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
 The primary objective is to determine if BPL&apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical response &gt;60%. The secondary objectives are: 1) to determine the safety of GAMMAPLEX at the dosage used in this study. 2) to determine if GAMMAPLEX maintains platelet counts of &#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical data. 
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
2013-02 
</date>
</status_block>
<start_date>
<date>
  2007-09
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
  2011-08
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2011-08
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Open Label
</design>
<design>
  Single Group Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  1
</number_of_arms>
<primary_outcome>
<measure>
  The Number of Subjects With Chronic ITP Treated With Gammaplex Whose Platelet Count Reached a Threshold of 50 x 10^9/L.
</measure>
<time_frame>
  9 days
</time_frame>
<description>
<textblock>
The  number of  subjects   with chronic ITP treated following treatment with Gammaplex who attained a  platelet  count  of  &#8805;  50  x  10^9/L  by  Day              9. 
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  The Safety of GAMMAPLEX at the Dosage Used in This Study.
</measure>
<time_frame>
  AEs were documented from the date the informed consent form was signed until the End of Study visit on Day 90.
</time_frame>
<description>
<textblock>
  The safety variables used to assess safety were the following:
  &#8226;	Adverse events
  -	The number and percent of infusions with at least 1 adverse event(AE) that occurs during an infusion or within 72 hours after the infusion stops
  -	Nature, severity, and frequency of AEs
  -	Suspected unexpected serious adverse reactions (SUSARs)
 
  &#8226;	Vital signs
  &#8226;	Clinical laboratory tests and Direct Coombs&apos; Test
  &#8226;	Transmission of viruses
  &#8226;	Physical examination
</textblock>
</description>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Duration of Time That the Platelet Count of Subjects With Chronic ITP Treated With Gammaplex Remained &#8805; 50 x 10^9/L.
</measure>
<time_frame>
  Days 1, 2, 3, 5, 9, 14, 21, 32.
</time_frame>
<description>
<textblock>
  Blood samples were collected to measure platelet counts and the duration of time for which the platelet count remained &#8805;50 x 10^9/L was measured.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  35
</enrollment>
<condition>
  Chronic Idiopathic Thrombocytopenic Purpura
</condition>
<arm_group>
<arm_group_label>
  Gammaplex (intravenous immunoglobulin)
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Biological/Vaccine
</intervent_type>
<primary_name>
  Gammaplex, intravenous immunoglobulin
</primary_name>
<description>
<textblock>
  Dosage form: Gammaplex&#174; is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex&#174; contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).
  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
</textblock>
</description>
<arm_group_label>
  Gammaplex (intravenous immunoglobulin)
</arm_group_label>
<other_name>
  Gammaplex
</other_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
  1) Males and females aged between 18 and 70 years.  
  2) Confirmed diagnosis of chronic ITP of at least 6 months duration.
  3) Platelet count of less than or equal to 20 x 10 9/L at enrollment.  
  4) Absence of other conditions that, in the opinion of the investigator, could cause thrombocytopenia.  
  5) If subjects were treated with corticosteroids the treatment regimen/dose must have been stable (for a minimum of 2 weeks before screening).  The dose of corticosteriod or other immunosuppressant should have remained constant until Day 32. 6) If subjects were being treated with cyclophosphamide, azathioprine or attenuated androgens, the treatment regimen and dose must have been stable for a minimum of 2 months before Day 1. The dose of corticosteriod or other immunosuppressant should have remained constant until Day 32. 7) Splenectomized subjects and both Rh(D)+ and Rh(D)- subjects may be included.  
  8) The subject has signed an informed consent form (subjects must be at least 18 years old), and/or the subject&apos;s legal guardian has signed the informed consent form if indicated
  9) If a subject is a female of child-bearing potential, she must have a negative result on a urine-based HCG pregnancy test.  
  10) If a subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study. 
 
  Exclusion Criteria:
  1) A history of any severe or anaphylactic reaction to blood or any blood-derived product, or any severe reaction to IGIV or any other IgG preparation.  
  2) Intolerance to any component of the investigational product.  
  3) Received any live virus vaccine within the last 3 months prior to Day1.  
  4) Received an IGIV preparation within 1 month prior to  Day 1.  
  5) Were currently receiving, or has received, any investigational agent within the 1 month prior to  Day 1.    
  6) Received any blood, blood product, or blood derivative within the 1 month prior to Day 1.  
  7)  Received Rituximab within the 3 months before Day 1.  
  8) Pregnant or nursing.  
  9) Tested positive for any of the following at screening: HBsAg, NAT for HCV, NAT for HIV, Antibodies to HCV or HIV 1 or 2. 
  10) Had levels greater than 2.5 times the upper limit of normal at screening, as defined by the central laboratory, of alanine aminotransferase or aspartate aminotransferase.  
  11) Had  severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); on dialysis; a history of acute renal failure.  
  12) Known to have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within the past 12 months.  
  13)History of deep vein thrombosis (DVT) or thrombotic complications of IGIV therapy.  
  14) Any history or sign of hyperviscosity, transient ischemic attack (TIA), stroke, other thromboembolic event, or unstable angina.  
  15) Suffered from any acute or chronic medical conditions (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing enteropathy) that, in the opinion of the investigator, may interfere with the conduct of the study.  
  16) An acquired medical condition, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (defined as an absolute neutrophil count (ANC) &lt; 1 x 109/L).  
  17) Non-controlled arterial hypertension (systolic blood pressure &gt;160 mmHg and/or diastolic blood pressure &gt;90 mmHg).  
  18) Anemic (hemoglobin &lt;10 g/dL) at screening.  
  19) Unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  70 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Principal Investigator
</role>
<name>
  Tim J Aldwinckle, MD
</name>
<affiliation>
<agency>
  Bio Products Laboratory
</agency>
</affiliation>
</investigator>
<location>
<facility>
<name>
  Mid Florida Hematology &amp; Oncology
</name>
<address>
<city>
  Orange City
</city>
<state>
  Florida
</state>
<zip>
  32763
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Sandy Davis
</name>
<phone>
  386-566-3303
</phone>
<phone_ext>
</phone_ext>
<email>
  swarrington@auafl.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Gregory Ortega, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Rush University Medical Center
</name>
<address>
<city>
  Chicago
</city>
<state>
  Illinois
</state>
<zip>
  60612
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Lisa N. Boggio, MD
</name>
<phone>
  312-942-5157
</phone>
<phone_ext>
</phone_ext>
<email>
  Lisa_Boggio@rush.edu
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Lisa N. Boggio, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Center for Cancer &amp; Blood Disorders
</name>
<address>
<city>
  Bethesda
</city>
<state>
  Maryland
</state>
<zip>
  20817
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Natalie Bongiorno, RN, MSHS
</name>
<phone>
  301-571-2016
</phone>
<phone_ext>
</phone_ext>
<email>
  nbongiorno@ccbdmd.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Victor Priego, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  New York Hospital / Cornell University, Division of Pediatrics
</name>
<address>
<city>
  New York
</city>
<state>
  New York
</state>
<zip>
  10021
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Jared Levan
</name>
<phone>
  212-746-3423
</phone>
<phone_ext>
</phone_ext>
<email>
  jal2029@med.cornell.edu
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  James B Bussel, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Department of Pediatrics, SUNY at Stony Brook
</name>
<address>
<city>
  Stony Brook
</city>
<state>
  New York
</state>
<zip>
  11794-8111
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Carol Martin
</name>
<phone>
  631-638-0838
</phone>
<phone_ext>
</phone_ext>
<email>
  caamartin@notes.cc.sunysb.edu
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Robert Parker, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Oregon Health &amp; Science University
</name>
<address>
<city>
  Portland
</city>
<state>
  Oregon
</state>
<zip>
  97239
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Jenifer Borruel Rector, RN BSN CCRC
</name>
<phone>
  503-494-7187
</phone>
<phone_ext>
</phone_ext>
<email>
  borruelr@ohsu.edu
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Lynn Boshkov, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Cancer Care Centers of South Texas
</name>
<address>
<city>
  San Antonio
</city>
<state>
  Texas
</state>
<zip>
  78229
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Joanne Hardy, RN
</name>
<phone>
  210-595-5683
</phone>
<phone_ext>
</phone_ext>
<email>
  joanne.hardy@usoncology.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Roger M Lyons, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  I. A. D. T. (Instituto Argentino de Diagn&#243;stico y Tratamiento)
</name>
<address>
<city>
  Buenos Aires
</city>
<state>
</state>
<zip>
  C1122AAL
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Cecilia Marin
</name>
<phone>
  005411 49638661
</phone>
<phone_ext>
</phone_ext>
<email>
  ce.marin@gmail.com
</email>
</contact>
<contact>
<name>
  Olivia Avila
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Claudio Iastrebner, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Britanico
</name>
<address>
<city>
  Buenos Aires
</city>
<state>
</state>
<zip>
  C1280AEB
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Laura Bullorsky
</name>
<phone>
  005411 4309 6400
</phone>
<phone_ext>
  2560
</phone_ext>
<email>
  laurabullo@hotmail.com &lt;laurabullo@hotmail.com&gt;
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Eduardo Bullorsky, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Centro de Educaci&#243;n M&#233;dica e Investigaciones Clinicas Dr. Norberto Quirno (CEMIC)
</name>
<address>
<city>
  Buenos Aires
</city>
<state>
</state>
<zip>
  C1431FWO
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Stella Zarza
</name>
<phone>
  0054 11 4546 8285
</phone>
<phone_ext>
</phone_ext>
<email>
  stezarza@yahoo.com.ar &lt;stezarza@yahoo.com.ar&gt;
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Juan Carlos Dupont, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Privado de Cordoba
</name>
<address>
<city>
  Cordoba
</city>
<state>
</state>
<zip>
  X5016KEH
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Lucrecia Audisio
</name>
<phone>
  0054 3514688243
</phone>
<phone_ext>
</phone_ext>
<email>
  investigacion.onco.hp@gmail.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Juan Garcia, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  J.R. Vidal Hospital
</name>
<address>
<city>
  Corrientes
</city>
<state>
</state>
<zip>
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Maria Gabriela Erro
</name>
<phone>
  03783 421 225
</phone>
<phone_ext>
</phone_ext>
<email>
  gabrielaerro@gmail.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Emilio Lanari, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Churruca
</name>
<address>
<city>
  Capital Federal
</city>
<state>
  Buenos Aires
</state>
<zip>
  C1437JCP
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Laura Valicenti
</name>
<phone>
  0054 11 4912 3049/3949/5045
</phone>
<phone_ext>
</phone_ext>
<email>
  hematologiachurruca@gmail.com &lt;hematologiachurruca@gmail.com&gt;
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Luis Palmer, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Italiano de La Plata
</name>
<address>
<city>
  La Plata
</city>
<state>
  Buenos Aires
</state>
<zip>
  B1900AXU
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Cecilia Benetti
</name>
<phone>
  0054 02214537200
</phone>
<phone_ext>
</phone_ext>
<email>
  ceciliabenetti@live.com.ar
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Alicia Enrico, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  CER San Juan
</name>
<address>
<city>
  San Juan
</city>
<state>
  San Juan
</state>
<zip>
  5400
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Mayra Bacil
</name>
<phone>
  0054 0264 4211086
</phone>
<phone_ext>
</phone_ext>
<email>
  mayrabacil@cersanjuan.com.ar
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Maria Gomez, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Instituto de Diagn&#243;stico Hematol&#243;gico Ambulatorio (IDHEA)
</name>
<address>
<city>
  Rosario
</city>
<state>
  Sante Fe
</state>
<zip>
  S2000JKR
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Jorgelina Safail
</name>
<phone>
  0054 341 4205500
</phone>
<phone_ext>
</phone_ext>
<email>
  jsafail@hotmail.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Ider Cerutti, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Sir Ganga Ram Hospital
</name>
<address>
<city>
  New Delhi
</city>
<state>
</state>
<zip>
  110060
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Ajeet Nanda
</name>
<phone>
  91-11-43594466
</phone>
<phone_ext>
</phone_ext>
<email>
  nanda.ajeet@gmail.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Anupama Jaggia, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Apollo Hospitals
</name>
<address>
<city>
  Hyderabad
</city>
<state>
  Andhra Pradesh
</state>
<zip>
  500003
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Venkat
</name>
<phone>
  91-9848018804
</phone>
<phone_ext>
</phone_ext>
<email>
  cvpr01@aherf-smo.org
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  S.V.S.S. Prasad, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Mahavir Hospital
</name>
<address>
<city>
  Hyderabad
</city>
<state>
  Andhra Pradesh
</state>
<zip>
  500054
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Madhuri Mahajan
</name>
<phone>
  91-40-23497392
</phone>
<phone_ext>
</phone_ext>
<email>
  madhurisamirmahajan@yahoo.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Srinivas Kulkarni, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  City Cancer Centre,
</name>
<address>
<city>
  Suryarao pet, Vijayawada
</city>
<state>
  Andhra Pradesh
</state>
<zip>
  520002
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Jayanth Atmakuru
</name>
<phone>
  91-9885256059
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Gopichand Mamillapalli&#160;&#160;, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  M. S Ramaiah Hospital
</name>
<address>
<city>
  Karnataka
</city>
<state>
  Bangalore
</state>
<zip>
  560054
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Vatsala Jayant, MD
</name>
<phone>
  91-080-40528403
</phone>
<phone_ext>
</phone_ext>
<email>
  vatsala.gm@metropolisindia.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Arun Narayan, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Vedanta
</name>
<address>
<city>
  Ahmedabad
</city>
<state>
  Gujarat
</state>
<zip>
  380009
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Hiren Shah, MD
</name>
<phone>
  09825407551
</phone>
<phone_ext>
</phone_ext>
<email>
  hirenshah27@gmail.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Sandip A Shah, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  M S Patel Cancer Centre, Shree Krishna Hospital
</name>
<address>
<city>
  Gokal Nagar, Karamsad
</city>
<state>
  Gujarat
</state>
<zip>
  388325
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Chirag Patel
</name>
<phone>
  91-269-2222411
</phone>
<phone_ext>
</phone_ext>
<email>
  chiragp@charutarhealth.org
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Chiramana Haritha, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Gurukrupa Hospital
</name>
<address>
<city>
  Ahmedabad
</city>
<state>
  Gujarat
</state>
<zip>
  380061
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Jay S Patel
</name>
<phone>
  91-79-27454181
</phone>
<phone_ext>
</phone_ext>
<email>
  jay.clinicalresearch@yahoo.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Rakesh Sharma, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Vinaya Hospital &amp; research Centre
</name>
<address>
<city>
  Mangalore
</city>
<state>
  Karnataka
</state>
<zip>
  5750003
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  S Nithin, MD
</name>
<phone>
  09900412690
</phone>
<phone_ext>
</phone_ext>
<email>
  drnithins@hotmail.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Hansraj Alva, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Kasturba Medical College, Manipal Acunova KMC Research Centre
</name>
<address>
<city>
  Mangalore
</city>
<state>
  Karnataka
</state>
<zip>
  575001
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Meera Lobo
</name>
<phone>
  09880200593
</phone>
<phone_ext>
</phone_ext>
<email>
  meera.lobo@ecronacunova.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  M Chakrapani, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Father Muller Medical College Hospital
</name>
<address>
<city>
  Mangalore
</city>
<state>
  Karnataka
</state>
<zip>
  575002
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Gouri Shenoy
</name>
<phone>
  91-824-2238285
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  B. M. Venkatesha, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Manipal Hospital
</name>
<address>
<city>
  Bangalore
</city>
<state>
  Karnataka
</state>
<zip>
  560017
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Manu Somnath
</name>
<phone>
  91-80-25024632
</phone>
<phone_ext>
</phone_ext>
<email>
  manu.somanath@ecronacunova.com,
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Ashish Dixit, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Deenanath Mangeshkar Hospital
</name>
<address>
<city>
  Pune
</city>
<state>
  Maharashtra
</state>
<zip>
  411004
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Shweta Shende
</name>
<phone>
  91-9766249644
</phone>
<phone_ext>
</phone_ext>
<email>
  shwetashende@gmail.com
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Sameer Melinkeri, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  S.K. Soni Hospital Sect 5
</name>
<address>
<city>
  Jaipur
</city>
<state>
  Rajasthan
</state>
<zip>
  300201
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Terminated
</status>
<contact>
<name>
  Priyan Yadav
</name>
<phone>
  09784861002
</phone>
<phone_ext>
</phone_ext>
<email>
  priyanyadav@yahoo.co.in
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Anish Maru, MD
</name>
</contact>
</location>
<see_also>
<annotation>
<textblock>
  Sponsor website
</textblock>
</annotation>
<url>
  http://www.bpl.co.uk
</url>
</see_also>
<keyword>
  Idiopathic Thrombocytopenic Purpura
</keyword>
<keyword>
  Bleeding disorders
</keyword>
<keyword>
  Immune System and Disorders
</keyword>
<initial_release_date>
  2007-07-18
</initial_release_date>
<last_release_date>
2013-02-13 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
  2012-05-04
</init_results_release_date>
<clinical_result>
<baseline>
<baselinemeasures>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
3 
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  &lt;=18 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
29 
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Between 18 and 65 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  3
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  &gt;=65 years
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Age Categorical
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  18
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  36
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Mean
</parametertype>
<title>
  Age Continuous
</title>
<unitofmeasure>
  years
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  26
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Female
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  9
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Male
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Gender, Male/Female
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  9
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  United States
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  5
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Argentina
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<nacomment>
</nacomment>
<parametervalue>
  21
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  India
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Region of Enrollment
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
</baselinemeasures>
<baselinereportinggroups>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.1"
>
<description>
<textblock>
  The first course of GAMMAPLEX was administered as an intravenous infusion of 1g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen was administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
</textblock>
</description>
<subjectsanalyzed>
  35
</subjectsanalyzed>
<title>
  GAMMAPLEX
</title>
</baselinereportinggroup>
</baselinereportinggroups>
<totalbaselinereportinggroup
 id="Baseline-TotalBaselineRptGroup"
>
<subjectsanalyzed>
  35
</subjectsanalyzed>
<title>
  Total
</title>
</totalbaselinereportinggroup>
</baseline>
<certainagreement>
<otherdetails>
<textblock>
  Publication of the Study results will be allowed only with prior written approval from Sponsor, said consent not to be unreasonably withheld. At the request of Sponsor, the Institution and/or Investigator shall delete any Confidential Information pertaining to Sponsor&apos;s Inventions from any proposed publications prior to submitting or presenting the materials. Any and all publications will give appropriate recognition of any support received from Sponsor.
</textblock>
</otherdetails>
<pisponsoremployee>
  No
</pisponsoremployee>
<restrictiontype>
  OTHER
</restrictiontype>
<restrictiveagreement>
  Yes
</restrictiveagreement>
</certainagreement>
<lastupdatetimestamp>
2013-02-13T08:42:21-05:00 
</lastupdatetimestamp>
<limitationsandcaveats>
<description>
</description>
</limitationsandcaveats>
<outcomemeasures>
<outcomemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.1-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
  60
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
  100
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
29 
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
The  number of  subjects   with chronic ITP treated following treatment with Gammaplex who attained a  platelet  count  of  &#8805;  50  x  10^9/L  by  Day              9. 
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  9 days
</timeframe>
<title>
  The Number of Subjects With Chronic ITP Treated With Gammaplex Whose Platelet Count Reached a Threshold of 50 x 10^9/L.
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<anticipatedresultpostingdate>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.1-OutcomeRptGroup.1"
>
<description>
<textblock>
  The first course of GAMMAPLEX was administered as an intravenous infusion of 1g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen was administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
</textblock>
</description>
<subjectsanalyzed>
  35
</subjectsanalyzed>
<title>
  GAMMAPLEX
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Any subject who started treatment with GAMMAPLEX and whose central laboratory results taken prior to infusion on Day 1 were within specified protocol parameters,  was included in the intent-to-treat (ITT) population for analysis of efficacy and safety.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  95% Confidence Interval
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.2-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
  1.8
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
  23.1
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  8.6
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  The safety variables used to assess safety were the following:
  &#8226;	Adverse events
  -	The number and percent of infusions with at least 1 adverse event(AE) that occurs during an infusion or within 72 hours after the infusion stops
  -	Nature, severity, and frequency of AEs
  -	Suspected unexpected serious adverse reactions (SUSARs)
 
  &#8226;	Vital signs
  &#8226;	Clinical laboratory tests and Direct Coombs&#8217; Test
  &#8226;	Transmission of viruses
  &#8226;	Physical examination
</textblock>
</measuredescription>
<parametertype>
  Number
</parametertype>
<timeframe>
  AEs were documented from the date the informed consent form was signed until the End of Study visit on Day 90.
</timeframe>
<title>
  The Safety of GAMMAPLEX at the Dosage Used in This Study.
</title>
<unitofmeasure>
  % of subjects with product related SAEs
</unitofmeasure>
<anticipatedresultpostingdate>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.2-OutcomeRptGroup.1"
>
<description>
<textblock>
  The first course of Gammaplex was administered as an intravenous infusion of 1g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen was administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
</textblock>
</description>
<subjectsanalyzed>
  35
</subjectsanalyzed>
<title>
  GAMMAPLEX
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Any subject who started treatment with GAMMAPLEX and whose central laboratory results taken prior to infusion on Day 1 were within specified protocol parameters,  was included in the intent-to-treat (ITT) population for analysis of efficacy and safety.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  Yes
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  95% Confidence Interval
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionlowerlimit>
  7
</dispersionlowerlimit>
<dispersionspread>
</dispersionspread>
<dispersionupperlimit>
  14
</dispersionupperlimit>
<nacomment>
</nacomment>
<parametervalue>
  10
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Blood samples were collected to measure platelet counts and the duration of time for which the platelet count remained &#8805;50 x 10^9/L was measured.
</textblock>
</measuredescription>
<parametertype>
  Median
</parametertype>
<timeframe>
  Days 1, 2, 3, 5, 9, 14, 21, 32.
</timeframe>
<title>
  Duration of Time That the Platelet Count of Subjects With Chronic ITP Treated With Gammaplex Remained &#8805; 50 x 10^9/L.
</title>
<unitofmeasure>
  days
</unitofmeasure>
<anticipatedresultpostingdate>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.1"
>
<description>
<textblock>
  The first course of GAMMAPLEX was administered as an intravenous infusion of 1g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen was administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
</textblock>
</description>
<subjectsanalyzed>
  35
</subjectsanalyzed>
<title>
  GAMMAPLEX
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Any subject who started treatment with GAMMAPLEX and whose central laboratory results taken prior to infusion on Day 1 were within specified protocol parameters, was included in the intent-to-treat (ITT) population for analysis of efficacy and safety.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
</outcomemeasures>
<participantflow>
<participantflowgroups>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.1"
>
<description>
<textblock>
  The first course of GAMMAPLEX was administered as an intravenous infusion of 1g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen was administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
</textblock>
</description>
<title>
  GAMMAPLEX
</title>
</flowgroup>
</participantflowgroups>
<periods>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  27
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Adverse Event
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  5
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Lost to Follow-up
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
</otherreasonname>
<reasontype>
  Withdrawal by Subject
</reasontype>
</dropwithdrawreason>
<dropwithdrawreason>
<dropwithdrawreasondetails>
<reasondetail>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<subjectsaffected>
  1
</subjectsaffected>
</reasondetail>
</dropwithdrawreasondetails>
<otherreasonname>
  Required other therapeutic intervention
</otherreasonname>
<reasontype>
  Other
</reasontype>
</dropwithdrawreason>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  8
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  35
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Overall Study
</title>
</period>
</periods>
<preassignmentdescription>
<textblock>
  This was an open label study.  All enrolled subjects received study medication.
</textblock>
</preassignmentdescription>
<recruitmentdetails>
<textblock>
  First enrollment: 04 September 2007.
  Last Subject completed: 05 August 2011.
  Thirty-five sites in the United States, India and  Argentina, all hospital clinics.
</textblock>
</recruitmentdetails>
</participantflow>
<pointofcontact>
<email>
  Tim.Aldwinckle@bpl.co.uk
</email>
<organizationname>
  Bio Products Laboratory Limited
</organizationname>
<phoneextension>
</phoneextension>
<phonenumber>
  +44 2089572565
</phonenumber>
<title>
  Tim Aldwinckle, MD
</title>
</pointofcontact>
<recordstatus>
  RELEASED
</recordstatus>
<reportedevents>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<frequencyreportingthreshold>
  5
</frequencyreportingthreshold>
<frequentadverseevents>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Abdominal pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Abdominal pain upper
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  5
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Blood and lymphatic system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Anaemia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  4
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Arthralgia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  6
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Injury, poisoning and procedural complications
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Contusion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Cough
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  5
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Ecchymosis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Epistaxis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Fatigue
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Gastritis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  7
</numevents>
<numsubjectsaffected>
  4
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Gingival bleeding
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Hypertension
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  8
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Nausea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Neck pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  4
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Pain
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Pain in extremity
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  7
</numevents>
<numsubjectsaffected>
  7
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Skin and subcutaneous tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Petechiae
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  10
</numevents>
<numsubjectsaffected>
  6
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Pyrexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Reproductive system and breast disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Vaginal haemorrhage
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  11
</numevents>
<numsubjectsaffected>
  8
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
</sourcevocabulary>
<term>
  Vomiting
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  21
</numevents>
<numsubjectsaffected>
  11
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
</sourcevocabulary>
<term>
  Headache
</term>
</frequentevent>
</frequentadverseevents>
<interventiongroups>
<interventiongroup
 id="ReportedEvents-InterventionGroup.1"
>
<description>
<textblock>
  The first course of GAMMAPLEX was administered as an intravenous infusion of 1g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen was administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.
</textblock>
</description>
<numsubjectsfrequentevents>
  21
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  4
</numsubjectsseriousevents>
<partatriskfrequentevents>
  35
</partatriskfrequentevents>
<partatriskseriousevents>
  35
</partatriskseriousevents>
<title>
  GAMMAPLEX
</title>
</interventiongroup>
</interventiongroups>
<notes>
</notes>
<seriousadverseevents>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Metabolism and nutrition disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Dehydration
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Diarrhoea
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  3
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Headache
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Pneumonia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Sepsis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  35
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (8.1)
</sourcevocabulary>
<term>
  Vomiting
</term>
</seriousevent>
</seriousadverseevents>
<sourcevocabulary>
</sourcevocabulary>
<timeframe>
  An event was only included in the analysis of Adverse Events (AEs) if it had an onset date between the first GAMMAPLEX infusion and 30 days after the last GAMMAPLEX infusion, inclusive.
</timeframe>
</reportedevents>
</clinical_result>
</clinical_study>
